Press Releases

DatePress Releases 
Nov 23rd, 2020Genenta to appoint Stephen Squinto, experienced biotech executive and investor, as Chairman
Nov 16th, 2020Genenta’s TemferonTM: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
Sep 30th 2020Genenta to present preliminary Phase I/II clinical data on TemferonTM in glioblastoma multiforme at Chardan’s 4th Annual Genetic Medicines Conference
Sep 8th, 2020Genenta presents company’s pipeline and the preliminary clinical data from Phase I/II in patients affected with glioblastoma multiforme at the Advanced Therapies Congress & Expo 2020
Jul 30th, 2020Genenta to present at the LifeSci Partners Summer Symposium
Jul 30th, 2020Genenta presents the company overview at the Access China Forum 2020
May 15th 2020Genenta presents at ASGCT preliminary pre-clinical and clinical data from TemferonTM Phase 1/2 study in patients with glioblastoma multiforme
May 4th 2020Genenta presents preliminary pre-clinical and clinical data from a Phase 1/2 study in patients with glioblastoma multiforme at American Society of Gene & Cell Therapy
Dec 4th 2019Genenta presents preliminary clinical data from a Phase 1/2 study in patients with glioblastoma multiforme at international scientific meetings in Europe and the USA. Genenta will attend the American Society of Hematology Conference in Orlando (USA)
Nov 27th, 2019Genenta has been Awarded the First Prize at China-Italy Best Start Up Showcase & Entrepreneurship Competition 2018/2019 (BSSEC). Genenta Presented at the China-Italy Innovation Forum2019 in Beijing (China)
Nov 5th 2019Genenta Science to present at NUO Capital Event in Hong Kong, BioCentury Healthcare Summit in Shanghai, and at Jefferies London Healthcare Conference
Oct 14th 2019Genenta has been Awarded to be the First Prize at China-Italy Best Start Up Showcase & Entrepreneurship Competition 2018/2019 (BSSEC)
Sep 30th 2019Genenta Science to present at Chardan Genetic 3rd Medicines Conference and Jefferies Gene Therapy/Editing Summit on Tuesday, October 08 – NYC
Sep 11th 2019Genenta Science announces 13,2 Million in a New Round of Financing, hits a total above 30 Million since inception. Two clinical trials ongoing.
Sep 11th 2019成立至今总计募得超过 3000 万欧元融资 Genenta Science 宣布完成新一轮 1320 万欧元融资 基于基因疗法治疗癌症的两项临床试验进展顺利
Mar 7th 2019MolMed and Genenta Science confirm and extend their partnership in the oncology field.
Sep 13th 2017Genenta Raised other $8,4 Million (€7 Million) in the Second Round of Financing – Total Raised in Two Rounds, $20,4 Million (€17 Million)
Jan 19th 2017Carlo Russo, M.D. joins Genenta Science as Chief Medical Officer
Sep 20th 2016Genenta and Ospedale San Raffaele Announce a Strategic Collaboration with Amgen to Explore Hematopoietic Stem Cell Gene Therapy in Oncology
Mar 21st 2016MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors
Mar 5th 2015The Italian Biotech Start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, raised a Euro 10 million ($11 million) Series A round with the support of Banca Esperia.
Jan 23rd 2015The Italian Biotech Start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, raised Euro 6.2 million (USD 7.2 million) with the support of Banca Esperia. And aims to close the Series A round at Euro 10 million (USD 11.6 million).
Sep 11th 2014The Italian Biotech Start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, raised a Euro 10 million ($11 million) Series A round with the support of Banca Esperia.